---
schema_version: "secwatch.filing_event.v1"
accession: "0001698530-25-000004"
form_type: "8-K"
ticker: "XCUR"
cik: "0001698530"
company_name: "EXICURE, INC."
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T19:50:51.513057+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Exicure buys GPCR USA for ~$1.62M; milestone & royalty deal with GPCR Therapeutics

## Summary
- Acquired all outstanding shares of GPCR Therapeutics USA from GPCR Therapeutics for ~$0.27/share (total ~$1.62M).
- Entered License and Collaboration Agreement to develop and commercialize GPCR's IP; includes milestone payments and 10% royalty on net sales.
- Example milestone: $30M payment when first annual net sales exceed $400M.
- Deal closed concurrently with execution on January 19, 2025.

## SEC filing metadata
- accession: 0001698530-25-000004
- form_type: 8-K
- ticker: XCUR
- cik: 0001698530
- company_name: EXICURE, INC.
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1698530/000169853025000004/0001698530-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1698530/000169853025000004/xcur-20250119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001698530-25-000004
- JSON: https://secwatch.observer/filing/0001698530-25-000004.json
- Plain text: https://secwatch.observer/filing/0001698530-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.